The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Company to launch product after the expiry of semaglutide patent in India
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
This marks the second indication for which gumokimab has gained NDA review acceptance
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Subscribe To Our Newsletter & Stay Updated
